Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.

IF 2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL International Journal of General Medicine Pub Date : 2025-01-29 eCollection Date: 2025-01-01 DOI:10.2147/IJGM.S502644

Chun Ling, Nengneng Cao, Huiping Wang, Yang Wan, Xue Liang, Jinjing Guo, Meng Xiao, Qiguo Zhang, Zhimin Zhai

{"title":"Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.","authors":"Chun Ling, Nengneng Cao, Huiping Wang, Yang Wan, Xue Liang, Jinjing Guo, Meng Xiao, Qiguo Zhang, Zhimin Zhai","doi":"10.2147/IJGM.S502644","DOIUrl":null,"url":null,"abstract":"Background: Acute Myeloid Leukemia (AML) is a prevalent neoplastic disorder. The roles of E3 ubiquitin ligases and related genes in AML drug resistance and prognosis remain unclear.Methods: Genes were identified from GeneCards and UniProt databases, differentially expressed genes were selected based on transcriptional sequencing data from wild-type and Adriamycin-resistant HL60 (HL60/WT & HL60/ADR) cell lines, and the intersection of these three sources was taken. We then constructed a prognostic model comprising five genes (HBP1, RNF130, RMND5B, TRIM32, and UBE2L3) through univariate Cox and LASSO regression analyses in the TCGA cohort and validated it in the BeatAML2.0 cohort. Finally, the expression of UBE2L3 was verified in cell lines and clinical case specimens.Results: The model accurately predicted AML prognosis and identified the UBE2L3 gene within the model as a high-risk biomarker associated with drug resistance, significantly influencing AML outcomes.Conclusion: The high expression of UBE2L3 is a reliable biomarker for drug resistance and poor prognosis of acute myeloid leukemia.","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"459-472"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787778/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S502644","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute Myeloid Leukemia (AML) is a prevalent neoplastic disorder. The roles of E3 ubiquitin ligases and related genes in AML drug resistance and prognosis remain unclear.

Methods: Genes were identified from GeneCards and UniProt databases, differentially expressed genes were selected based on transcriptional sequencing data from wild-type and Adriamycin-resistant HL60 (HL60/WT & HL60/ADR) cell lines, and the intersection of these three sources was taken. We then constructed a prognostic model comprising five genes (HBP1, RNF130, RMND5B, TRIM32, and UBE2L3) through univariate Cox and LASSO regression analyses in the TCGA cohort and validated it in the BeatAML2.0 cohort. Finally, the expression of UBE2L3 was verified in cell lines and clinical case specimens.

Results: The model accurately predicted AML prognosis and identified the UBE2L3 gene within the model as a high-risk biomarker associated with drug resistance, significantly influencing AML outcomes.

Conclusion: The high expression of UBE2L3 is a reliable biomarker for drug resistance and poor prognosis of acute myeloid leukemia.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

E3连接酶相关基因的系统分析发现UBE2L3是急性髓系白血病耐药相关的预后生物标志物。

背景：急性髓系白血病（AML）是一种常见的肿瘤疾病。E3泛素连接酶及相关基因在AML耐药及预后中的作用尚不清楚。方法：从GeneCards和UniProt数据库中鉴定基因，根据野生型和耐阿霉素HL60 （HL60/WT和HL60/ADR）细胞株的转录测序数据选择差异表达基因，并取这三个来源的交叉点。然后，我们在TCGA队列中通过单变量Cox和LASSO回归分析构建了包含五个基因（HBP1、RNF130、RMND5B、TRIM32和UBE2L3）的预后模型，并在BeatAML2.0队列中进行了验证。最后，在细胞系和临床病例标本中验证UBE2L3的表达。结果：该模型准确预测AML预后，并将模型内UBE2L3基因识别为与耐药相关的高危生物标志物，显著影响AML预后。结论：UBE2L3高表达是急性髓系白血病耐药和预后不良的可靠生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of General Medicine Medicine-General Medicine

自引率

0.00%

发文量

1113

审稿时长

16 weeks

期刊介绍： The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.